Dimitris Anagnostakis is emblematic of Boehringer Ingelheim’s corporate values as evidenced by his 26-year loyalty to the company promoting the advancement of innovation. As the General Manager spearheading the only multinational company with manufacturing operations in Greece, he shares his insights on the company’s robust portfolio, navigating the difficulties of an unstable pharmaceutical environment, as well as how the company contributes to the Greek economy as a whole.
Mr. Anagnotakis, your entire 26-year career has been with B.I. in a multitude of different functions – from your start as a sales representative, to heading the hospital department, then the marketing department, being a regional manager for France/Italy/Spain, and now General Manager of Greece. How has Boehringer Ingelheim’s commitment to Greece solidified over the years?
"The painful realities of the Greek pharmaceutical landscape revolve around two main topics: delays in market access, exacerbated by clawbacks and rebates."
